Agios Pharmaceuticals, Inc. (AGIO) Stock
AGIO Key Statistics
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
CEO: Brian Goff. Company website
AGIO — Frequently Asked Questions
What is the AGIO stock price today?
Agios Pharmaceuticals, Inc. (AGIO) trades at $32.82, up 3.34% on the day, as of Nov 12, 2026 09:38 UTC.
What is Agios Pharmaceuticals, Inc.'s market cap?
Agios Pharmaceuticals, Inc. has a market capitalisation of $1.96B, calculated from the live AGIO share price and shares outstanding.
What is the P/E ratio of AGIO?
AGIO has no meaningful price-to-earnings ratio: Agios Pharmaceuticals, Inc. lost $6.32 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Agios Pharmaceuticals, Inc. make?
Agios Pharmaceuticals, Inc. generated revenue of $140.84M over the trailing twelve months, which puts the stock at 13.91 times sales.
What is the 52-week range for AGIO?
AGIO has traded between $22.24 and $46.00 over the past 52 weeks, and the last price is 28.7% below that high.
Is Agios Pharmaceuticals, Inc. profitable?
No. Agios Pharmaceuticals, Inc. is loss-making, with a net margin of -264.76% over the trailing twelve months.
What is the analyst price target for AGIO?
Wall Street analysts rate AGIO Buy, with an average price target of $40.67, 23.9% above the current price.
What sector is Agios Pharmaceuticals, Inc. in?
Agios Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Agios Pharmaceuticals, Inc.?
Brian Goff is the chief executive of Agios Pharmaceuticals, Inc., which employs 540 people.
Where can I track AGIO in real time?
QFI Terminal shows AGIO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See AGIO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open AGIO in Terminal See plans